Valiant Laboratories Publishes Q1 FY27 Financial Results
Valiant Laboratories Limited published its audited standalone and consolidated financial results for Q1 FY27, ended June 30, 2026. Standalone and consolidated total income from operations was ₹74.27 crore, with net profit after tax at ₹9.48 crore. The results were approved by the Board on August 10, 2026.
Publication of quarterly financial results is a material event for investors, impacting investment decisions and stock valuation.
The announcement is a routine publication of financial results and newspaper dissemination, with no significant positive or negative indicators in the provided text.
Valiant Laboratories Limited has announced the publication of its audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were published in the Financial Express (English) and Mumbai Lakshadeep (Marathi) newspapers on August 12, 2026. The company's total income from operations (net) for the standalone results was ₹74.27 crore, with a net profit after tax of ₹9.48 crore. For the consolidated results, the total income from operations (net) was ₹74.27 crore, and the net profit after tax was ₹9.48 crore.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 10, 2026. The detailed financial results are available on the websites of BSE Limited (www.bseindia.com), NSE (www.nseindia.com), and the company's own website (www.valiantlabs.in).
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.